We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Penwest Pharmaceuticals Shareholders Approve Merger With Subsidiary of Endo Pharmaceuticals PR Newswire PATTERSON, N.Y., Nov. 4, 2010 PATTERSON, N.Y., Nov. 4, 2010 /PRNewswire-FirstCall/ -- At a...
Endo Pharmaceuticals Reports Strong Third Quarter 2010 Financial Results; Reaffirms 2010 Financial Guidance and Provides Financial Guidance for 2011 PR Newswire CHADDS FORD, Pa., Nov. 1, 2010...
Penwest Pharmaceuticals Announces Intention to Terminate NASDAQ Listing and Registration PR Newswire PATTERSON, N.Y., Oct. 15 PATTERSON, N.Y., Oct. 15 /PRNewswire-FirstCall/ -- Penwest...
Watson Pharmaceuticals Inc. (WPI) said it became the latest drug maker to win a license to sell a generic version of Opana extended-release pain-relief tablets in coming years after a patent...
Penwest Pharmaceuticals Sets Special Shareholders Meeting Date for Approval of Merger With Subsidiary of Endo Pharmaceuticals PR Newswire PATTERSON, N.Y., Sept. 30 PATTERSON, N.Y., Sept. 30...
Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals PR Newswire CHADDS FORD, Pa., Sept. 20 CHADDS FORD, Pa., Sept. 20 /PRNewswire-FirstCall/ -- Endo...
Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Penwest Pharmaceuticals, Co. (“Penwest” or the “Company”) (NasdaqGM:PPCO) concerning the...
The Law Office of Abe Shainberg is investigating the Board of Directors of Penwest Pharmaceuticals Co. (NasdaqGM: PPCO) for possible breaches of fiduciary duty and other...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Penwest Pharmaceuticals Co. (“Penwest” or the...
The Law Office of Vincent Wong is investigating the Board of Directors of Penwest Pharmaceuticals Co. (NasdaqGM: PPCO) for possible breaches of fiduciary duty and other...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions